ASH 2022 | Using a mass spectrometry-based blood test to assess M-protein levels in NDMM
Jean-Sébastien Claveau, MD, Mayo Clinic, Rochester, MN, discusses the results of a retrospective study which used Mass-Fix, a mass spectrometry (MS)-based blood test, to assess M-protein levels in patients with newly diagnosed multiple myeloma (NDMM) as an alternative to bone marrow examination. This study demonstrated that patients achieving sustained Mass-Fix negativity had an improved progression-free survival (PFS), suggesting that this method may be valuable in evaluating disease prognosis. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
